IP Library › Granted Patent US 12708627
Granted Patent B2
US 12708627 · App. 18/681,723 · Granted Aug 18, 2026

Combination therapy for VAV3 cancer

Inventors: Nicolas Nassar (Cincinnati, OH); Jose A. Cancelas (Cincinnati, OH)
Assignees: Children's Hospital Medical Center; UNIVERSITY OF CINCINNATI
A61K31/53A61K31/341A61K31/4184A61K31/444A61K31/5025A61P35/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12708627
App. No.
18/681,723
Granted
Aug 18, 2026
Kind
B2
Abstract

Disclosed herein are compositions and methods for treating an individual having a leukemia. In certain aspects, the methods may include administering an IODVA1 compound and ponatinib to an individual in need thereof for treatment of a leukemia, which may include, for example, TKI-resistant leukemia, TKI-resistant Ph+ B-ALL, Chronic Myelogenous Leukemia (CML), Ph-Positive Acute Lymphoblastic Leukemia (ALL), Ph-like ALL, Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML), MLL-rearranged B-ALL, and VAV3 positive leukemia.

Claims (12)

1 . A method of treating an individual having a leukemia comprising

administering a compound having the structure

or a tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the individual; and

administering ponatinib to the individual.

2 . The method of claim 1 , the compound being administered at one or more time points selected from prior to administration of the ponatinib, concurrent with administration of the ponatinib, or following administration of the ponatinib.

3 . The method of claim 1 , the compound IODVA1 being administered via one or more routes selected from orally and intravenously.

4 . The method of claim 1 , the ponatinib being administered via one or more routes selected from orally and intravenously.

5 . The method of claim 1 , the leukemia being selected from a Tyrosine Kinase Inhibitor resistant (TKI-resistant) leukemia, a TKI-resistant Ph+B-ALL, Chronic Myelogenous Leukemia (CML), Ph-Positive Acute Lymphoblastic Leukemia (ALL), Ph-like ALL, Chronic Myeloid Leukemia, Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML), MLL-rearranged B-ALL, and combinations thereof.

6 . The method of claim 1 , wherein the leukemia is not a RAC-deficient leukemia.

7 . The method of claim 1 , wherein the leukemia is a VAV3 positive leukemia.

8 . The method of claim 1 , the individual having a p210-BCR-ABL1(T3151) mutation.

9 . The method of claim 1 , the individual being a pediatric individual.